Lung Cancer Market 2027 By Diagnostic, Therapeutic | The Insight Partners

Lung Cancer Market to 2027 - Global Analysis and Forecasts by Diagnostic (Test, Technology); Therapeutic (Disease Type, Molecule Type)

Report Code: TIPRE00003018 | No. of Pages: 150 | Category: Medical Device | Status: Upcoming
MARKET INTRODUCTION

Lung Cancer is an uncontrolled unwanted growth of cells abnormally in one or both lungs of an individual, which decreases the ability of lungs to provide oxygen into the blood stream increasing the tumor or cell growth. This is largely seen in individuals prone to smoking habits and may result into death if untreated on time.

MARKET DYNAMICS

The Lung Cancer market is anticipated to grow in the forecast, owing to the factors such as growing prevalence of cancer, rising population who smoke, introduction of novel and innovative products and market players getting involved in introduction of therapies and drugs.

MARKET SCOPE

The "Global Lung Cancer Market Analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of Lung Cancer market with detailed market segmentation by diagnostic, therapeutic and geography. The global Lung Cancer market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Lung Cancer market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global Lung Cancer market is segmented on the basis of diagnostic and therapeutic. Based on diagnostic the market is segmented into tests, technologies. Based therapeutic disease type, molecule type.
REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Lung Cancer market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Lung Cancer market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Lung Cancer market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Lung Cancer market in these regions.

MARKET PLAYERS

The reports cover key developments in the Lung Cancer market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Lung Cancer market are anticipated to lucrative growth opportunities in the future with the rising demand for Lung Cancer market in the global market. Below mentioned is the list of few companies engaged in the Lung Cancer market.

The report also includes the profiles of Lung Cancer market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  Quest Diagnostics
  •  AstraZeneca
  •  GlaxoSmithKline
  •  Agennix
  •  Eli Lilly
  •  Boston Biomedical
  •  F. Hoffmann-La Roche Ltd
  •  Siemens Healthcare GmbH
  •  Oncimmune Holdings Plc
  •  QIAGEN
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
 1.1. SCOPE OF THE STUDY
 1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
 1.3. MARKET SEGMENTATION
 1.3.1 Lung Cancer Market - By Diagnostic
 1.3.2 Lung Cancer Market - By Therapeutic
 1.3.3 Lung Cancer Market - By Region
 1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LUNG CANCER MARKET LANDSCAPE
 4.1. OVERVIEW
 4.2. PEST ANALYSIS
 4.2.1 North America - Pest Analysis
 4.2.2 Europe - Pest Analysis
 4.2.3 Asia-Pacific - Pest Analysis
 4.2.4 Middle East and Africa - Pest Analysis
 4.2.5 South and Central America - Pest Analysis
 4.3. EXPERT OPINIONS
5. LUNG CANCER MARKET - KEY MARKET DYNAMICS
 5.1. KEY MARKET DRIVERS
 5.2. KEY MARKET RESTRAINTS
 5.3. KEY MARKET OPPORTUNITIES
 5.4. FUTURE TRENDS
 5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LUNG CANCER MARKET - GLOBAL MARKET ANALYSIS
 6.1. LUNG CANCER - GLOBAL MARKET OVERVIEW
 6.2. LUNG CANCER - GLOBAL MARKET AND FORECAST TO 2027
 6.3. MARKET POSITIONING/MARKET SHARE
7. LUNG CANCER MARKET - REVENUE AND FORECASTS TO 2027 - DIAGNOSTIC
 7.1. OVERVIEW
 7.2. DIAGNOSTIC MARKET FORECASTS AND ANALYSIS
 7.3. TEST
 7.3.1. Overview
 7.3.2. Test Market Forecast and Analysis
 7.3.3. Spuctum cytology Market
 7.3.3.1. Overview
 7.3.3.2. Spuctum cytology Market Forecast and Analysis
 7.3.4. Bopsy Market
 7.3.4.1. Overview
 7.3.4.2. Bopsy Market Forecast and Analysis
 7.3.5. Imaging Market
 7.3.5.1. Overview
 7.3.5.2. Imaging Market Forecast and Analysis
 7.3.6. Molecular Test Market
 7.3.6.1. Overview
 7.3.6.2. Molecular Test Market Forecast and Analysis
 7.3.7. Others Market
 7.3.7.1. Overview
 7.3.7.2. Others Market Forecast and Analysis
 7.4. TECHNOLOGY
 7.4.1. Overview
 7.4.2. Technology Market Forecast and Analysis
 7.4.3. Fluorescent In Situ Hybridization Market
 7.4.3.1. Overview
 7.4.3.2. Fluorescent In Situ Hybridization Market Forecast and Analysis
 7.4.4. Immunohistochemical Market
 7.4.4.1. Overview
 7.4.4.2. Immunohistochemical Market Forecast and Analysis
 7.4.5. Others Market
 7.4.5.1. Overview
 7.4.5.2. Others Market Forecast and Analysis
8. LUNG CANCER MARKET - REVENUE AND FORECASTS TO 2027 - THERAPEUTIC
 8.1. OVERVIEW
 8.2. THERAPEUTIC MARKET FORECASTS AND ANALYSIS
 8.3. DISEASE TYPE
 8.3.1. Overview
 8.3.2. Disease Type Market Forecast and Analysis
 8.3.3. Non-Small Cell Lung Cancer Market
 8.3.3.1. Overview
 8.3.3.2. Non-Small Cell Lung Cancer Market Forecast and Analysis
 8.3.4. Small Cell Lung Cancer Market
 8.3.4.1. Overview
 8.3.4.2. Small Cell Lung Cancer Market Forecast and Analysis
 8.4. MOLECULE TYPE
 8.4.1. Overview
 8.4.2. Molecule Type Market Forecast and Analysis
 8.4.3. Small Molecules Market
 8.4.3.1. Overview
 8.4.3.2. Small Molecules Market Forecast and Analysis
 8.4.4. Biologics Market
 8.4.4.1. Overview
 8.4.4.2. Biologics Market Forecast and Analysis
9. LUNG CANCER MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
 9.1. NORTH AMERICA
 9.1.1 North America Lung Cancer Market Overview
 9.1.2 North America Lung Cancer Market Forecasts and Analysis
 9.1.3 North America Lung Cancer Market Forecasts and Analysis - By Diagnostic
 9.1.4 North America Lung Cancer Market Forecasts and Analysis - By Therapeutic
 9.1.5 North America Lung Cancer Market Forecasts and Analysis - By Countries
 9.1.5.1 United States Lung Cancer Market
 9.1.5.1.1 United States Lung Cancer Market by Diagnostic
 9.1.5.1.2 United States Lung Cancer Market by Therapeutic
 9.1.5.2 Canada Lung Cancer Market
 9.1.5.2.1 Canada Lung Cancer Market by Diagnostic
 9.1.5.2.2 Canada Lung Cancer Market by Therapeutic
 9.1.5.3 Mexico Lung Cancer Market
 9.1.5.3.1 Mexico Lung Cancer Market by Diagnostic
 9.1.5.3.2 Mexico Lung Cancer Market by Therapeutic
 9.2. EUROPE
 9.2.1 Europe Lung Cancer Market Overview
 9.2.2 Europe Lung Cancer Market Forecasts and Analysis
 9.2.3 Europe Lung Cancer Market Forecasts and Analysis - By Diagnostic
 9.2.4 Europe Lung Cancer Market Forecasts and Analysis - By Therapeutic
 9.2.5 Europe Lung Cancer Market Forecasts and Analysis - By Countries
 9.2.5.1 Germany Lung Cancer Market
 9.2.5.1.1 Germany Lung Cancer Market by Diagnostic
 9.2.5.1.2 Germany Lung Cancer Market by Therapeutic
 9.2.5.2 France Lung Cancer Market
 9.2.5.2.1 France Lung Cancer Market by Diagnostic
 9.2.5.2.2 France Lung Cancer Market by Therapeutic
 9.2.5.3 Italy Lung Cancer Market
 9.2.5.3.1 Italy Lung Cancer Market by Diagnostic
 9.2.5.3.2 Italy Lung Cancer Market by Therapeutic
 9.2.5.4 Spain Lung Cancer Market
 9.2.5.4.1 Spain Lung Cancer Market by Diagnostic
 9.2.5.4.2 Spain Lung Cancer Market by Therapeutic
 9.2.5.5 United Kingdom Lung Cancer Market
 9.2.5.5.1 United Kingdom Lung Cancer Market by Diagnostic
 9.2.5.5.2 United Kingdom Lung Cancer Market by Therapeutic
 9.3. ASIA-PACIFIC
 9.3.1 Asia-Pacific Lung Cancer Market Overview
 9.3.2 Asia-Pacific Lung Cancer Market Forecasts and Analysis
 9.3.3 Asia-Pacific Lung Cancer Market Forecasts and Analysis - By Diagnostic
 9.3.4 Asia-Pacific Lung Cancer Market Forecasts and Analysis - By Therapeutic
 9.3.5 Asia-Pacific Lung Cancer Market Forecasts and Analysis - By Countries
 9.3.5.1 Australia Lung Cancer Market
 9.3.5.1.1 Australia Lung Cancer Market by Diagnostic
 9.3.5.1.2 Australia Lung Cancer Market by Therapeutic
 9.3.5.2 China Lung Cancer Market
 9.3.5.2.1 China Lung Cancer Market by Diagnostic
 9.3.5.2.2 China Lung Cancer Market by Therapeutic
 9.3.5.3 India Lung Cancer Market
 9.3.5.3.1 India Lung Cancer Market by Diagnostic
 9.3.5.3.2 India Lung Cancer Market by Therapeutic
 9.3.5.4 Japan Lung Cancer Market
 9.3.5.4.1 Japan Lung Cancer Market by Diagnostic
 9.3.5.4.2 Japan Lung Cancer Market by Therapeutic
 9.3.5.5 South Korea Lung Cancer Market
 9.3.5.5.1 South Korea Lung Cancer Market by Diagnostic
 9.3.5.5.2 South Korea Lung Cancer Market by Therapeutic
 9.4. MIDDLE EAST AND AFRICA
 9.4.1 Middle East and Africa Lung Cancer Market Overview
 9.4.2 Middle East and Africa Lung Cancer Market Forecasts and Analysis
 9.4.3 Middle East and Africa Lung Cancer Market Forecasts and Analysis - By Diagnostic
 9.4.4 Middle East and Africa Lung Cancer Market Forecasts and Analysis - By Therapeutic
 9.4.5 Middle East and Africa Lung Cancer Market Forecasts and Analysis - By Countries
 9.4.5.1 South Africa Lung Cancer Market
 9.4.5.1.1 South Africa Lung Cancer Market by Diagnostic
 9.4.5.1.2 South Africa Lung Cancer Market by Therapeutic
 9.4.5.2 Saudi Arabia Lung Cancer Market
 9.4.5.2.1 Saudi Arabia Lung Cancer Market by Diagnostic
 9.4.5.2.2 Saudi Arabia Lung Cancer Market by Therapeutic
 9.4.5.3 U.A.E Lung Cancer Market
 9.4.5.3.1 U.A.E Lung Cancer Market by Diagnostic
 9.4.5.3.2 U.A.E Lung Cancer Market by Therapeutic
 9.5. SOUTH AND CENTRAL AMERICA
 9.5.1 South and Central America Lung Cancer Market Overview
 9.5.2 South and Central America Lung Cancer Market Forecasts and Analysis
 9.5.3 South and Central America Lung Cancer Market Forecasts and Analysis - By Diagnostic
 9.5.4 South and Central America Lung Cancer Market Forecasts and Analysis - By Therapeutic
 9.5.5 South and Central America Lung Cancer Market Forecasts and Analysis - By Countries
 9.5.5.1 Brazil Lung Cancer Market
 9.5.5.1.1 Brazil Lung Cancer Market by Diagnostic
 9.5.5.1.2 Brazil Lung Cancer Market by Therapeutic
 9.5.5.2 Argentina Lung Cancer Market
 9.5.5.2.1 Argentina Lung Cancer Market by Diagnostic
 9.5.5.2.2 Argentina Lung Cancer Market by Therapeutic
10. INDUSTRY LANDSCAPE
 10.1. MERGERS AND ACQUISITIONS
 10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
 10.3. NEW PRODUCT LAUNCHES
 10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. LUNG CANCER MARKET, KEY COMPANY PROFILES
 11.1. QUEST DIAGNOSTICS
 11.1.1. Key Facts
 11.1.2. Business Description
 11.1.3. Products and Services
 11.1.4. Financial Overview
 11.1.5. SWOT Analysis
 11.1.6. Key Developments
 11.2. ASTRAZENECA
 11.2.1. Key Facts
 11.2.2. Business Description
 11.2.3. Products and Services
 11.2.4. Financial Overview
 11.2.5. SWOT Analysis
 11.2.6. Key Developments
 11.3. GLAXOSMITHKLINE
 11.3.1. Key Facts
 11.3.2. Business Description
 11.3.3. Products and Services
 11.3.4. Financial Overview
 11.3.5. SWOT Analysis
 11.3.6. Key Developments
 11.4. AGENNIX
 11.4.1. Key Facts
 11.4.2. Business Description
 11.4.3. Products and Services
 11.4.4. Financial Overview
 11.4.5. SWOT Analysis
 11.4.6. Key Developments
 11.5. ELI LILLY
 11.5.1. Key Facts
 11.5.2. Business Description
 11.5.3. Products and Services
 11.5.4. Financial Overview
 11.5.5. SWOT Analysis
 11.5.6. Key Developments
 11.6. BOSTON BIOMEDICAL
 11.6.1. Key Facts
 11.6.2. Business Description
 11.6.3. Products and Services
 11.6.4. Financial Overview
 11.6.5. SWOT Analysis
 11.6.6. Key Developments
 11.7. F. HOFFMANN-LA ROCHE LTD
 11.7.1. Key Facts
 11.7.2. Business Description
 11.7.3. Products and Services
 11.7.4. Financial Overview
 11.7.5. SWOT Analysis
 11.7.6. Key Developments
 11.8. SIEMENS HEALTHCARE GMBH
 11.8.1. Key Facts
 11.8.2. Business Description
 11.8.3. Products and Services
 11.8.4. Financial Overview
 11.8.5. SWOT Analysis
 11.8.6. Key Developments
 11.9. ONCIMMUNE HOLDINGS PLC
 11.9.1. Key Facts
 11.9.2. Business Description
 11.9.3. Products and Services
 11.9.4. Financial Overview
 11.9.5. SWOT Analysis
 11.9.6. Key Developments
 11.10. QIAGEN
 11.10.1. Key Facts
 11.10.2. Business Description
 11.10.3. Products and Services
 11.10.4. Financial Overview
 11.10.5. SWOT Analysis
 11.10.6. Key Developments
12. APPENDIX
 12.1. ABOUT THE INSIGHT PARTNERS
 12.2. GLOSSARY OF TERMS

 

The List of Companies

- Quest Diagnostics
- AstraZeneca
- GlaxoSmithKline
- Agennix
- Eli Lilly
- Boston Biomedical
- F. Hoffmann-La Roche Ltd
- Siemens Healthcare GmbH
- Oncimmune Holdings Plc
- QIAGEN